Post-exposure prophylaxis with a maraviroc-containing regimen after occupational exposure to a multi-resistant HIV-infected source person.
We report the case of a health care worker who received a post-exposure prophylaxis including an investigational drug, maraviroc, after a needle stick percutaneous injury to an HIV-infected patient with late-stage disease and harboring a multi-drug resistant virus. Post-exposure prophylaxis including maraviroc was pursued for a total of 28 days, with a weekly clinical and biological evaluation. Post-exposure prophylaxis was well tolerated, with no increase in liver function tests. The health care worker remained HIV-negative after a 6-month follow-up.
Méchai
Frédéric
F
1/AP-HP, Internal Medicine and Infectious Diseases Department, Bicêtre University Hospital, Paris XI University, Le Kremin-Bicêtre, France.
Quertainmont
Yann
Y
Sahali
Sabrinel
S
Delfraissy
Jean-François
JF
Ghosn
Jade
J
D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D003510:Cyclohexanes / Q000627:therapeutic use*; D024921:Drug Resistance, Multiple, Viral; D015658:HIV Infections / Q000517:prevention & control* / Q000635:transmission; D015497:HIV-1 / Q000187:drug effects; D006282:Health Personnel; D006801:Humans; D017758:Infectious Disease Transmission, Patient-to-Professional; D008297:Male; D000077592:Maraviroc; D008875:Middle Aged; D016602:Needlestick Injuries; D016273:Occupational Exposure; D014230:Triazoles / Q000627:therapeutic use*
D019380:Anti-HIV Agents; D003510:Cyclohexanes; D014230:Triazoles; D000077592:Maraviroc